Upsher-Smith Recalls Bexarotene Capsules Due to Dissolution Failures
Upsher-Smith Laboratories is recalling 166 bottles of Bexarotene 75 mg capsules because they failed to meet dissolution specifications.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which typically involves a temporary or medically reversible adverse health consequence. The hazard is a failure to meet dissolution specifications, which is a quality control issue rather than a direct contamination or acute injury risk.
Plain-English summary
Upsher-Smith Laboratories, Inc. is recalling 166 bottles of Bexarotene Capsules, 75 mg, 100 capsules per bottle. The product is identified by NDC 0832-0285-00, Lot A2610, and an expiration date of 3/2020.
The recall was initiated because the product failed to meet dissolution specifications. This means the capsules may not release the medication in the body as intended, potentially affecting the drug's effectiveness.
The affected product was distributed in Kentucky, Ohio, New Jersey, and Louisiana. Consumers and healthcare providers should stop using the recalled product and contact their healthcare provider or pharmacist for guidance on obtaining a replacement.
The recalled product
- Product
- BEXAROTENE (BEXAROTENE)
- Brand
- BEXAROTENE
- Manufacturer
- Upsher Smith Laboratories, Inc.
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 166
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot: A2610. exp 3/2020
UPCs (1)
- 0308320285009
Distribution
Related recalls
Same manufacturer · Upsher Smith Laboratories, Inc.
See all →- SevereUpsher Smith Recalls Bumetanide Tablets for Unspecified Degradation Product
FDA (Drugs) · 2018-10-31
- ModerateUpsher Smith Recalls Bumetanide Tablets for Unspecified Degradation Product
FDA (Drugs) · 2018-10-31
- LowUpsher Smith Recalls Oxandrolone Tablets Due to Missing Primary Labels
FDA (Drugs) · 2014-04-30
- ModerateUpsher Smith Recalls Propranolol Hydrochloride Capsules for Dissolution Failure
FDA (Drugs) · 2013-02-20
- LowUpsher Smith Recalls Divalproex Sodium Tablets Due to Labeling Error
FDA (Drugs) · 2013-01-23
Same hazard · dissolution failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- ModerateChlorthalidone 25mg tablets failed dissolution specifications in two batches
FDA (Drugs) · 2026-06-24
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- ModerateMinocycline extended-release tablets failed dissolution testing during stability analysis
FDA (Drugs) · 2026-06-17